

Priya Kumthekar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/441748/publications.pdf>

Version: 2024-02-01

109
papers

2,505
citations

257450

24
h-index

223800

46
g-index

122
all docs

122
docs citations

122
times ranked

3494
citing authors

#	ARTICLE	IF	CITATIONS
1	Leptomeningeal metastases: the future is now. <i>Journal of Neuro-Oncology</i> , 2022, 156, 443-452.	2.9	11
2	Targeting HER2+ Breast Cancer Brain Metastases: A Review of Brain-Directed HER2-Directed Therapies. <i>CNS Drugs</i> , 2022, 36, 167-179.	5.9	6
3	Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort. <i>Neuro-Oncology</i> , 2022, 24, 1726-1735.	1.2	18
4	Updates on Molecular Targeted Therapies for Intraparenchymal CNS Metastases. <i>Cancers</i> , 2022, 14, 17.	3.7	3
5	Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial. <i>Neuro-Oncology Advances</i> , 2022, 4, vdab186.	0.7	1
6	Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2022, 24, 1613-1646.	1.2	39
7	Advances in the Diagnosis and Treatment of Leptomeningeal Disease. <i>Current Neurology and Neuroscience Reports</i> , 2022, 22, 413-425.	4.2	4
8	The PROTECT Study: A phase II, open-label trial of prophylactic skin toxicity therapy with clindamycin and triamcinolone in patients with glioblastoma treated with tumor-treating fields.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS2084-TPS2084.	1.6	0
9	Investigating the impact of NGS data availability on clinical decision-making in brain cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2032-2032.	1.6	0
10	Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2026-2026.	1.6	0
11	Digital monitoring and assessments in patients with glioblastoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2045-2045.	1.6	0
12	Factors affecting time to brain metastases for stage 2 and 3 breast cancer patients: A large single-institutional analysis with potential screening implications. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab009.	0.7	2
13	A broad perspective on evaluating bias in the neuro-oncology workplace. <i>Neuro-Oncology</i> , 2021, 23, 498-499.	1.2	3
14	A first-in-human phase 0 clinical study of RNA interference–based spherical nucleic acids in patients with recurrent glioblastoma. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	136
15	Stalking the Diagnosis. <i>New England Journal of Medicine</i> , 2021, 384, 1262-1267.	27.0	0
16	Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1277.	7.4	63
17	De novo purine biosynthesis is a major driver of chemoresistance in glioblastoma. <i>Brain</i> , 2021, 144, 1230-1246.	7.6	30
18	An investigation into the impact of next generation sequencing on the use of targeted treatments in glioblastoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2035-2035.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Multi-center, single arm phase II study of the dual mTORC1/mTORC2 inhibitor vistusertib for patients with recurrent or progressive grade II-III meningiomas.. Journal of Clinical Oncology, 2021, 39, 2024-2024.	1.6	4
20	A phase 1/2 study of selinexor in combination with standard of care therapy for newly diagnosed or recurrent glioblastoma.. Journal of Clinical Oncology, 2021, 39, TPS2071-TPS2071.	1.6	0
21	Trial in progress: Phase I/II study of radiation therapy followed by intrathecal trastuzumab/pertuzumab in the management of HER2⁺ breast leptomeningeal disease.. Journal of Clinical Oncology, 2021, 39, TPS1099-TPS1099.	1.6	7
22	Alliance A071601: Phase II trial of BRAF/MEK inhibition in newly diagnosed papillary craniopharyngiomas.. Journal of Clinical Oncology, 2021, 39, 2000-2000.	1.6	18
23	Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study. Journal of Clinical Oncology, 2021, 39, 2667-2675.	1.6	58
24	Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase I, dose-escalation trial. Lancet Oncology, The, 2021, 22, 1103-1114.	10.7	91
25	Glioblastoma as an age-related neurological disorder in adults. Neuro-Oncology Advances, 2021, 3, v125.	0.7	30
26	Discordance between central versus local response assessments in neuroendocrine tumor (NET) patients (pts) enrolled in A021202.. Journal of Clinical Oncology, 2021, 39, 361-361.	1.6	1
27	American Society of Clinical Oncology 2021 Annual Meeting updates on primary brain tumors and CNS metastatic tumors. Future Oncology, 2021, 17, 4425-4429.	2.4	0
28	NIMG-01. INTEROBSERVER VARIABILITY OF THE REVISED IMAGING SCORECARD FOR LEPTOMENINGEAL METASTASIS: A JOINT EORTC BRAIN TUMOR GROUP AND RANO EFFORT. Neuro-Oncology, 2021, 23, vi126-vi127.	1.2	1
29	BIOM-05. CASE SERIES OF MULTI-INSTITUTIONAL UTILITY OF CNSide TO MANAGE LEPTOMENINGEAL DISEASE IN PATIENTS WITH METASTATIC BREAST CANCER. Neuro-Oncology, 2021, 23, vi10-vi10.	1.2	0
30	INNV-13. UNDERSTANDING FACTORS THAT INFLUENCE THE DECISION OF ACCEPTING TUMOR TREATING FIELDS (TTF) THERAPY. Neuro-Oncology, 2021, 23, vi107-vi108.	1.2	0
31	CTIM-11. PHASE 2 STUDY OF SL-701, A NOVEL IMMUNOTHERAPY, IN ADULTS WITH RECURRENT GBM: A HIGH PARAMETER FLOW CYTOMETRY ANALYSIS OF CD8+ T CELLS AND POTENTIAL IMPLICATIONS FOR PATIENT ENRICHMENT STRATEGIES. Neuro-Oncology, 2021, 23, vi51-vi51.	1.2	0
32	Advances in the diagnosis, evaluation, and management of leptomeningeal disease. Neuro-Oncology Advances, 2021, 3, v86-v95.	0.7	10
33	CTNI-53. RADIATION TREATMENT VOLUMES BEFORE AND AFTER BRAF/MEK THERAPY IN NEWLY DIAGNOSED PAPILLARY CRANIOPHARYNGIOMAS: A CORRELATIVE ANALYSIS OF THE ALLIANCE A071601 PHASE II TRIAL. Neuro-Oncology, 2021, 23, vi72-vi72.	1.2	0
34	CTNI-17. A PHASE 1 WITH DOSE EXPANSION/PHASE 2 STUDY OF SELINEXOR IN COMBINATION WITH STANDARD OF CARE THERAPY FOR NEWLY DIAGNOSED OR RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi62-vi63.	1.2	0
35	CTIM-12. A PHASE 1 TRIAL OF IMMUNORADIOTHERAPY WITH THE IDO ENZYME INHIBITOR (BMS-986205) AND NIVOLUMAB IN PATIENTS WITH NEWLY DIAGNOSED MGMT PROMOTER UNMETHYLATED IDHwt GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi51-vi52.	1.2	3
36	CTNI-54. A SINGLE ARM PHASE II STUDY OF THE DUAL MTOC1/MTOC2 INHIBITOR VISTUSERTIB PROVIDED FOR SPORADIC PATIENTS WITH GRADE II-III MENINGIOMAS THAT RECUR OR PROGRESS AFTER SURGERY AND RADIATION. Neuro-Oncology, 2021, 23, vi72-vi72.	1.2	0

#	ARTICLE	IF	CITATIONS
37	Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas. <i>Neuro-Oncology</i> , 2020, 22, 470-479.	1.2	49
38	Optimal Management of Corticosteroids in Patients with Intracranial Malignancies. <i>Current Treatment Options in Oncology</i> , 2020, 21, 77.	3.0	22
39	Sex-specific impact of patterns of imageable tumor growth on survival of primary glioblastoma patients. <i>BMC Cancer</i> , 2020, 20, 447.	2.6	20
40	In pursuit of a perpetually burning flame: preventing burnout in neuro-oncology. <i>Neuro-Oncology</i> , 2020, 22, 750-751.	1.2	1
41	Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma. <i>Clinical Cancer Research</i> , 2020, 26, 5232-5245.	7.0	52
42	Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer. <i>Journal of Neuro-Oncology</i> , 2020, 148, 599-606.	2.9	50
43	ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases. <i>Clinical Cancer Research</i> , 2020, 26, 2789-2799.	7.0	130
44	Leptomeningeal metastasis from solid tumors. <i>Journal of the Neurological Sciences</i> , 2020, 411, 116706.	0.6	34
45	Abstract P1-18-03: Pertuzumab (P) plus high-dose trastuzumab (H) for the treatment of central nervous system (CNS) progression after radiotherapy (RT) in patients (pts) with HER2-positive metastatic breast cancer (MBC): Primary efficacy analysis results from the phase II PATRICIA study. , 2020, , .		5
46	Alliance A071401: Phase II trial of FAK inhibition in meningiomas with somatic NF2 mutations.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2502-2502.	1.6	17
47	Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4003-4003.	1.6	2
48	Alliance A071701: Genomically guided treatment trial in brain metastases.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS2573-TPS2573.	1.6	4
49	Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1537-1570.	4.9	253
50	Post-operative disposition and readmission rates in repeat resections for glioblastoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, e14543-e14543.	1.6	0
51	QOLP-02. PATIENT-REPORTED OUTCOMES FOLLOWING PERTUZUMAB PLUS HIGH-DOSE TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER (MBC) AND CENTRAL NERVOUS SYSTEM (CNS) PROGRESSION POST-RADIOTHERAPY. <i>Neuro-Oncology</i> , 2020, 22, ii174-ii175.	1.2	0
52	IMMU-44. PRE-DIAGNOSTIC EOSINOPHIL LEVEL AND GLIOBLASTOMA DEVELOPMENT IN PATIENTS WITH AND WITHOUT ATOPIC DISEASE. <i>Neuro-Oncology</i> , 2020, 22, ii114-ii114.	1.2	0
53	Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	170
54	LPTO-02. INTRATHECAL (IT) TRASTUZUMAB (T) FOR THE TREATMENT OF LEPTOMENINGEAL DISEASE (LM) IN PATIENTS (PTS) WITH HUMAN EPIDERMAL RECEPTOR-2 POSITIVE (HER2+) CANCER: A MULTICENTER PHASE 1/2 STUDY. <i>Neuro-Oncology Advances</i> , 2019, 1, i6-i6.	0.7	9

#	ARTICLE	IF	CITATIONS
55	Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. <i>Neuro-Oncology</i> , 2019, 21, 106-114.	1.2	84
56	Pleomorphic xanthoastrocytoma: a brief review. <i>CNS Oncology</i> , 2019, 8, CNS39.	3.0	53
57	Lifetime Occurrence of Brain Metastases Arising from Lung, Breast, and Skin Cancers in the Elderly: A SEER-Medicare Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 917-925.	2.5	23
58	Comparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with Glioblastoma. <i>Clinical Cancer Research</i> , 2019, 25, 3259-3265.	7.0	24
59	ACTR-40. PHASE 2 SAFETY AND EFFICACY OF AR-67 (7-T-BUTYLDIMETHYLSILTYL-10-HYDROXYCAMPTOTHECIN) IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME (GBM) OR GLIOSARCOMA. <i>Neuro-Oncology</i> , 2019, 21, vi22-vi22.	1.2	1
60	CMET-16. A PHASE II TRIAL OF BEVACIZUMAB IN PATIENTS WITH RECURRENT SOLID TUMOR BRAIN METASTASES WHO HAVE PROGRESSED FOLLOWING WHOLE BRAIN RADIATION THERAPY (WBRT): FINAL RESULTS. <i>Neuro-Oncology</i> , 2019, 21, vi54-vi54.	1.2	0
61	CMET-11. RESPONSE TO STEREOTACTIC RADIOSURGERY FOR MULTIPLE BRAIN METASTASES BASED ON HISTOLOGY-SPECIFIC SUBTYPE STATUS. <i>Neuro-Oncology</i> , 2019, 21, vi53-vi53.	1.2	0
62	NIMG-58. SEX DIFFERENCES IN CONTRAST-ENHANCING GLIOMAS AT PRESENTATION. <i>Neuro-Oncology</i> , 2019, 21, vi174-vi174.	1.2	1
63	QOLP-31. ASSESSING THE IMPACT OF GLIOBLASTOMA ON WORK PRODUCTIVITY IN PATIENTS AND THEIR CAREGIVERS. <i>Neuro-Oncology</i> , 2019, 21, vi204-vi204.	1.2	0
64	QOLP-20. IMPACT OF GLIOBLASTOMA ON PATIENT-REPORTED SYMPTOM BURDEN AND PHYSICAL ACTIVITY ASSESSED BY CONVENTIONAL INSTRUMENTS AND A NOVEL DEVICE-BASED TECHNOLOGY. <i>Neuro-Oncology</i> , 2019, 21, vi201-vi202.	1.2	2
65	ATIM-33. INTERIM RESULTS OF A PHASE II MULTI-CENTER STUDY OF ONCOLYTIC ADENOVIRUS DNX-2401 WITH PEMBROLIZUMAB FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192). <i>Neuro-Oncology</i> , 2019, 21, vi8-vi9.	1.2	13
66	HOUT-11. EXTENSIVE BRAINSTEM INFILTRATION, NOT MASS EFFECT, IS A COMMON FEATURE OF END-STAGE CEREBRAL GLIOBLASTOMAS. <i>Neuro-Oncology</i> , 2019, 21, vi114-vi114.	1.2	1
67	ENvironmental Dynamics Underlying Responsive Extreme Survivors (ENDURES) of Glioblastoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 655-661.	1.3	3
68	INNV-19. SURVEYING BIAS IN NEURO-ONCOLOGY AND SOCIETY FOR NEURO ONCOLOGY (SNO) MEMBERS: GENDER AND BEYOND. <i>Neuro-Oncology</i> , 2019, 21, vi134-vi134.	1.2	1
69	Bevacizumab for the treatment of non-small cell lung cancer patients with synchronous brain metastases. <i>Scientific Reports</i> , 2019, 9, 17792.	3.3	13
70	Quality of Life of Family Caregivers of Patients With Cancer in KorÅše, Albania. <i>Journal of Palliative Care</i> , 2019, 34, 118-125.	1.0	7
71	A phase II trial of bevacizumab in patients with recurrent solid tumor brain metastases who have failed whole brain radiation therapy (WBRT).. <i>Journal of Clinical Oncology</i> , 2019, 37, 2070-2070.	1.6	5
72	A phase 0 first-in-human study using NU-0129: A gold base spherical nucleic acid (SNA) nanoconjugate targeting BCL2L12 in recurrent glioblastoma patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3012-3012.	1.6	30

#	ARTICLE	IF	CITATIONS
73	Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202).. Journal of Clinical Oncology, 2019, 37, 4005-4005.	1.6	29
74	Medical management of brain metastases and leptomeningeal disease in patients with breast carcinoma. Future Oncology, 2018, 14, 391-407.	2.4	22
75	Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation. Molecular Cancer Research, 2018, 16, 32-46.	3.4	29
76	Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma. Neuro-Oncology, 2018, 20, 838-847.	1.2	60
77	ATIM-02. TUMOR TREATING FIELDS IN COMBINATION WITH BEVACIZUMAB IN RECURRENT OR PROGRESSIVE MENINGIOMA IN A PHASE 2 STUDY. Neuro-Oncology, 2018, 20, vi1-vi1.	1.2	1
78	ATIM-06. PHASE 2 TRIAL OF SL-701 + BEVACIZUMAB IN PATIENTS WITH PREVIOUSLY TREATED GLIOBLASTOMA (GBM) MEETS PRIMARY ENDPOINT OF OS-12, WITH PRELIMINARY CORRELATION BETWEEN LONG-TERM SURVIVAL AND TARGET-SPECIFIC CD8+ T CELL IMMUNE RESPONSE. Neuro-Oncology, 2018, 20, vi2-vi2.	1.2	1
79	QOLP-11. QUALITY OF LIFE IN HIGH-GRADE GLIOMA PATIENTS ON A PHASE I VIROTHERAPY STUDY. Neuro-Oncology, 2018, 20, vi216-vi216.	1.2	1
80	QOLP-25. QUALITY OF LIFE FOLLOWING RE-IRRADIATION FOR RECURRENT HIGH GRADE GLIOMA. Neuro-Oncology, 2018, 20, vi220-vi220.	1.2	2
81	CMET-22. INTRATHECAL (IT) TRAZTUZUMAB (T) FOR THE TREATMENT OF LEPTOMENINGEAL METASTASES (LM) IN PATIENTS (PTS) WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE (HER2+) CANCER: A MULTICENTER PHASE 1/2 STUDY. Neuro-Oncology, 2018, 20, vi58-vi58.	1.2	9
82	NIMG-21. SEX DIFFERENCES IN EXTREME SURVIVORSHIP AMONG PRIMARY GLIOBLASTOMA PATIENTS. Neuro-Oncology, 2018, 20, vi180-vi180.	1.2	3
83	Phase 2 trial of SL-701 in relapsed/refractory (r/r) glioblastoma (GBM): Correlation of immune response with longer-term survival.. Journal of Clinical Oncology, 2018, 36, 2058-2058.	1.6	11
84	Phase I open-label, ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies: Dose selection for combination with PD-1 blockade.. Journal of Clinical Oncology, 2018, 36, 3075-3075.	1.6	2
85	A phase II study of atezolizumab (Atezo) combined with pertuzumab (P) and high-dose trastuzumab (H) for the treatment of central nervous system (CNS) metastases in patients with Her2-positive (HER2+) metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2018, 36, TPS1100-TPS1100.	1.6	0
86	Abstract CT081: Tumor treating fields in combination with Bevacizumab in recurrent or progressive meningioma in a phase II study. , 2018, , .		0
87	Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma. Neuro-Oncology, 2017, 19, now257.	1.2	80
88	Mutant IDH1 and seizures in patients with glioma. Neurology, 2017, 88, 1805-1813.	1.1	167
89	A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas. Journal of Neuro-Oncology, 2017, 133, 589-594.	2.9	22
90	ATIM-14. ALLIANCE A071101: A PHASE II RANDOMIZED TRIAL COMPARING THE EFFICACY OF HEAT SHOCK PROTEIN PEPTIDE COMPLEX-96 (HSPPC-96) VACCINE GIVEN WITH BEVACIZUMAB VERSUS BEVACIZUMAB ALONE IN THE TREATMENT OF SURGICALLY RESECTABLE RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2017, 19, vi29-vi29.	1.2	21

#	ARTICLE	IF	CITATIONS
91	Gene Delivery in Neuro-Oncology. <i>Current Oncology Reports</i> , 2017, 19, 69.	4.0	18
92	Efficacy analysis of ABT-414 with or without temozolomide (TMZ) in patients (pts) with EGFR-amplified, recurrent glioblastoma (rGBM) from a multicenter, international phase I clinical trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2003-2003.	1.6	9
93	Expanded phase I study of intratumoral Ad-RTS-hIL-12 plus oral veledimex: Tolerability and survival in recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2044-2044.	1.6	8
94	A pilot study of palbociclib in patients with HER2-positive breast cancer with brain metastasis.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS1110-TPS1110.	1.6	5
95	State-of-the-art considerations in small cell lung cancer brain metastases. <i>Oncotarget</i> , 2017, 8, 71223-71233.	1.8	47
96	Prognosis of older patients with low-grade glioma: A retrospective study. <i>Integrative Cancer Science and Therapeutics</i> , 2017, 4, .	0.1	3
97	Phase 1 open-label, multiple ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3075-3075.	1.6	3
98	ATIM-10. PHASE I/II TRIAL OF RADIATION THERAPY, TEMOZOLOMIDE AND PEMBROLIZUMAB FOLLOWED BY TEMOZOLOMIDE AND PEMBROLIZUMAB IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2016, 18, vi19-vi19.	1.2	1
99	Mutant IDH1 and thrombosis in gliomas. <i>Acta Neuropathologica</i> , 2016, 132, 917-930.	7.7	130
100	Improving vaccine efficacy against malignant glioma. <i>Oncolmmunology</i> , 2016, 5, e1196311.	4.6	16
101	Systemic therapies in the treatment of non-small-cell lung cancer brain metastases. <i>Future Oncology</i> , 2016, 12, 1045-1058.	2.4	10
102	ANG1005, a novel brain-penetrant taxane derivative, for the treatment of recurrent brain metastases and leptomeningeal carcinomatosis from breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2004-2004.	1.6	16
103	Effect of controlled intratumoral viral delivery of Ad-RTS-hIL-12 + oral veledimex in subjects with recurrent or progressive glioma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2052-2052.	1.6	2
104	MNGO-04PHASE II TRIAL OF BEVACIZUMAB IN PATIENTS WITH SURGERY AND RADIATION REFRACTORY PROGRESSIVE MENINGIOMA. <i>Neuro-Oncology</i> , 2015, 17, v130.4-v130.	1.2	7
105	Low-Grade Glioma. <i>Cancer Treatment and Research</i> , 2015, 163, 75-87.	0.5	61
106	Concordance of patient and caregiver reports in evaluating quality of life in patients with malignant gliomas and an assessment of caregiver burden. <i>Neuro-Oncology Practice</i> , 2014, 1, 47-54.	1.6	23
107	Financial burden experienced by patients undergoing treatment for malignant gliomas. <i>Neuro-Oncology Practice</i> , 2014, 1, 71-76.	1.6	9
108	Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases. <i>Journal of Neuro-Oncology</i> , 2013, 112, 247-255.	2.9	52

#	ARTICLE	IF	CITATIONS
109	Preclinical modeling in leptomenigeal disease: Starting at the foundation to tackle a difficult disease. Neuro-Oncology, 0, , .	1.2	0